Company intelligence / Profile preview

Deftbiotech

Daejeon, South Korea

Ownership: Private
Development stage: Other

Overview

Deftbiotech is a South Korean biotechnology company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company utilizes its proprietary DEFT platform to design small molecule degraders that target disease-causing proteins previously considered undruggable. Their lead programs focus on oncology indications, including STAT3 and GSPT1 degraders for various cancers. Deftbiotech aims to overcome the limitations of traditional inhibitors by completely removing pathogenic proteins from cells. The company is headquartered in Daejeon and is advancing its pipeline through pre-clinical development.

Therapeutic areas: Oncology
Modalities: Small moleculeProteolysis-targeting chimera therapyTargeted protein degradation
Industry: Biotech

Beyond the preview

Go deeper on Deftbiotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deftbiotech.

Explore the full profile